CULLINAN THERAPEUTICS INC. - COMMON STOCK

Cullinan Therapeutics to Present Results from REZILIENT1, a Phase 1/2 Trial of Zipalertinib in Patients with Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Who Have Received Prior Therapy, at ASCO 2025

23 Apr 2025 10:14:04 By Nasdaq GlobeNewswire

Cullinan Therapeutics Receives Approval from European Medicines Agency to Initiate Phase 1 Trial of CLN-978, a Bispecific CD19 T Cell Engager Administered Subcutaneously, in Patients with Rheumatoid Arthritis

16 Apr 2025 07:00:00 By Nasdaq GlobeNewswire

Cullinan Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results

27 Feb 2025 07:00:32 By Nasdaq GlobeNewswire

Cullinan Therapeutics to Participate in Upcoming Investor Conferences

24 Feb 2025 07:00:00 By Nasdaq GlobeNewswire

Cullinan Therapeutics to Participate in Fireside Chat at the Guggenheim Securities SMID Cap Biotech Conference

30 Jan 2025 07:00:00 By Nasdaq GlobeNewswire

Cullinan Therapeutics Announces Preclinical Data for CLN-978, a CD19-directed T Cell Engager, to be Presented at ACR Convergence 2024

14 Nov 2024 10:01:00 By Nasdaq GlobeNewswire

Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results

07 Nov 2024 07:00:01 By Nasdaq GlobeNewswire

Cullinan Therapeutics to Participate in Fireside Chat at Stifel 2024 Healthcare Conference

05 Nov 2024 07:00:00 By Nasdaq GlobeNewswire

Cullinan Therapeutics to Present Preclinical Data for CLN-978, a CD19-directed T Cell Engager, at ACR Convergence 2024

04 Nov 2024 07:00:00 By Nasdaq GlobeNewswire

Cullinan Therapeutics Receives U.S. FDA Clearance of Investigational New Drug Application for CLN-978 Administered Subcutaneously in Patients with Moderate to Severe Systemic Lupus Erythematosus

16 Oct 2024 07:00:00 By Nasdaq GlobeNewswire

Cullinan Therapeutics Receives Approval to Initiate its Global Phase 1 Clinical Trial of CLN-978 for the Treatment of Systemic Lupus Erythematosus

17 Sep 2024 07:00:00 By Nasdaq GlobeNewswire

Cullinan Therapeutics Announces Submission of Investigational New Drug Application to U.S. Food and Drug Administration for CLN-978 to Treat Systemic Lupus Erythematosus

16 Sep 2024 07:00:00 By Nasdaq GlobeNewswire

Cullinan Therapeutics Presents Positive Updated Data from Module C of Zipalertinib Pivotal Phase 2b Study at ESMO 2024

14 Sep 2024 04:15:00 By Nasdaq GlobeNewswire

Cullinan Therapeutics to Participate in Upcoming Investor Conferences

28 Aug 2024 08:00:00 By Nasdaq GlobeNewswire

Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results

08 Aug 2024 07:00:01 By Nasdaq GlobeNewswire

Cullinan Therapeutics Announces Positive Initial Data from Pivotal Phase 2b REZILIENT1 Study of Zipalertinib

01 Jun 2024 07:00:00 By Nasdaq GlobeNewswire

Cullinan Therapeutics to Participate in Fireside Chat at TD Cowen 5th Annual Oncology Innovation Summit

24 May 2024 08:00:00 By Nasdaq GlobeNewswire

Cullinan Therapeutics to Present First Data for CLN-619, a Novel Anti-MICA/B Antibody, in Combination with a Checkpoint Inhibitor and Updated Monotherapy Data at ASCO 2024

23 May 2024 17:04:38 By Nasdaq GlobeNewswire

Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results

15 May 2024 16:05:00 By Nasdaq GlobeNewswire

Cullinan Therapeutics Announces Appointment of Mary Kay Fenton as Chief Financial Officer

29 Apr 2024 07:00:00 By Nasdaq GlobeNewswire